EMA accepts Eisai, Biogen’s lecanemab MAA for review to treat AD
Lecanemab is an investigational anti-amyloid beta (Aβ) protofibril antibody intended to treat AD with confirmed amyloid pathology. On 6 January, it received accelerated approval from the US Food